Smith DF - Search Results

1

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Moreno J, Nieto J, Masina S, Cañavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J. Moreno J, et al. Among authors: smith df. Vaccine. 2007 Jul 20;25(29):5290-300. doi: 10.1016/j.vaccine.2007.05.010. Epub 2007 Jun 4. Vaccine. 2007. PMID: 17576026 Free PMC article.

2

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.

Stäger S, Smith DF, Kaye PM. Stäger S, et al. Among authors: smith df. J Immunol. 2000 Dec 15;165(12):7064-71. doi: 10.4049/jimmunol.165.12.7064. J Immunol. 2000. PMID: 11120835

3

Transgenic Leishmania and the immune response to infection.

Beattie L, Evans KJ, Kaye PM, Smith DF. Beattie L, et al. Among authors: smith df. Parasite Immunol. 2008 Apr;30(4):255-66. doi: 10.1111/j.1365-3024.2008.01020.x. Epub 2008 Feb 4. Parasite Immunol. 2008. PMID: 18266814 Free PMC article. Review.

4

Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.

Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, Losch FO, Fritz U, Walden P, Lacey CN, Smith DF, Aebischer T, Kaye PM. Maroof A, et al. Among authors: smith df, smith b. J Infect Dis. 2012 Mar 1;205(5):853-63. doi: 10.1093/infdis/jir842. Epub 2012 Feb 1. J Infect Dis. 2012. PMID: 22301630 Free PMC article.

5

In vivo recognition of ovalbumin expressed by transgenic Leishmania is determined by its subcellular localization.

Prickett S, Gray PM, Colpitts SL, Scott P, Kaye PM, Smith DF. Prickett S, et al. Among authors: smith df. J Immunol. 2006 Apr 15;176(8):4826-33. doi: 10.4049/jimmunol.176.8.4826. J Immunol. 2006. PMID: 16585577 Free PMC article.

6

Dynamic imaging of experimental Leishmania donovani-induced hepatic granulomas detects Kupffer cell-restricted antigen presentation to antigen-specific CD8 T cells.

Beattie L, Peltan A, Maroof A, Kirby A, Brown N, Coles M, Smith DF, Kaye PM. Beattie L, et al. Among authors: smith df. PLoS Pathog. 2010 Mar 12;6(3):e1000805. doi: 10.1371/journal.ppat.1000805. PLoS Pathog. 2010. PMID: 20300603 Free PMC article.

7

Functional analysis of Leishmania cyclopropane fatty acid synthetase.

Oyola SO, Evans KJ, Smith TK, Smith BA, Hilley JD, Mottram JC, Kaye PM, Smith DF. Oyola SO, et al. Among authors: smith ba, smith df, smith tk. PLoS One. 2012;7(12):e51300. doi: 10.1371/journal.pone.0051300. Epub 2012 Dec 10. PLoS One. 2012. PMID: 23251490 Free PMC article.

8

Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen.

Polley R, Stager S, Prickett S, Maroof A, Zubairi S, Smith DF, Kaye PM. Polley R, et al. Among authors: smith df. Infect Immun. 2006 Jan;74(1):773-6. doi: 10.1128/IAI.74.1.773-776.2006. Infect Immun. 2006. PMID: 16369038 Free PMC article.

9

Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses.

Stäger S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F, Kaye PM. Stäger S, et al. Among authors: smith df. Nat Med. 2003 Oct;9(10):1287-92. doi: 10.1038/nm933. Epub 2003 Sep 21. Nat Med. 2003. PMID: 14502281

10

Antigen-experienced T cells limit the priming of naive T cells during infection with Leishmania major.

Gray PM, Reiner SL, Smith DF, Kaye PM, Scott P. Gray PM, et al. Among authors: smith df. J Immunol. 2006 Jul 15;177(2):925-33. doi: 10.4049/jimmunol.177.2.925. J Immunol. 2006. PMID: 16818747 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

906 results

Search Page